22 July 2021  
EMA/CHMP/408323/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ultomiris 
ravulizumab 
On 22 July 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Ultomiris. 
The marketing authorisation holder for this medicinal product is Alexion Europe SAS. 
The CHMP adopted an extension to an existing indication as follows:2 
Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 
kg or above with paroxysmal nocturnal haemoglobinuria (PNH): 
• 
• 
in patients with haemolysis with clinical symptom(s) indicative of high disease activity. 
in patients who are clinically stable after having been treated with eculizumab for at least the past 
6 months (see section 5.1). 
Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical 
haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received 
eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
